[Skip to Navigation]
Comment & Response
July 2018

Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma

Author Affiliations
  • 1Kaiser Permanente, San Francisco, California
JAMA Dermatol. 2018;154(7):850-851. doi:10.1001/jamadermatol.2018.1229

To the Editor Treatment with topical fluorouracil, 5%, compared with placebo reduced risk of surgically treated squamous cell carcinoma (SCC) and Mohs surgery for keratinocyte carcinoma (KC) for 1 year, according to a randomized clinical trial (RCT) report.1 However, because neither of these outcomes was prespecified, these findings should be interpreted very cautiously and should not sway clinical practice.

Add or change institution